Determination of the effective dose delivered by image guided radiotherapy in head & neck and breast treatments

Evaluation of a Scintillating Plastic Optical Fiber Device for Measuring kV-Cone Beam Computed Tomography Dose

BACKGROUND

Justification of imaging procedures such as cone beam computed tomography (CBCT) in radiotherapy makes no doubt. However, the CBCT composite dose is rarely reported or optimized, even though the repeated CBCT cumulative dose can be up to 3% of the prescription dose. This study aimed to evaluate the performance and utility of a new plastic scintillating optical fiber dosimeter for CBCT dosimetric quality assurance (QA) applications before a potential application in patient composite CBCT dosimetry.

METHODS

The dosimeter, made of 1 mm diameter plastic fiber, was installed under a linear accelerator treatment table and linked to photodetectors. The fiber impact on the fluence and dose delivered was respectively assessed with an electronic portal imaging device (EPID) and EBT3 Gafchromic® film. The presence of artifacts was visually evaluated on kV images. The dosimeter performances were determined for various acquisition parameters by comparison with ionization chamber values.

RESULTS

The maximum impact of the fiber on the fluence measured by the EPID was -1.2% for the 6 MV flattening filter-free beam. However, the fiber did not alter the film dose profile when measured for all the beams tested. The fiber was not visible at energies ≥ 80 kV and was merely visible on the CBCT images. When the rate of images per second or mA was changed, the maximum relative difference between the device and the ionization chamber CTDIs was <5%. Changing collimation led to a -7.2% maximum relative difference with an absolute dose difference that was insignificant (-0.3 mGy). Changing kV was associated with a -8.7% maximum relative difference, as published in the literature.

CONCLUSIONS

The dosimeter may be a promising device for CBCT recurrent dosimetry quality control or dose optimization. According to these results, further developments are in progress in order to adapt the solution to the measurement of patient composite CBCT doses.

Evaluation of patient organ doses from kilovoltage cone-beam CT imaging in radiation therapy

Background

Currently, CBCT system is an indispensable component of radiation therapy units. Because of that, it is important in treatment planning and diagnosis. CBCT is also an crucial tool for patient positioning and verification in image-guided radiation therapy (IGRT). Therefore, it is critical to investigate the patient organ doses arising from CBCT imaging. The purpose of this study is to evaluate patient organ doses and effective dose to patients from three different protocols of Elekta Synergy XVI system for kV CBCT imaging examinations in image guided radiation therapy.

Materials and methods

Organ dose measurements were done with thermoluminescent dosimeters in Alderson RA NDO male phantom for head & neck (H&N), chest and pelvis protocols of the Elekta Synergy XVI kV CBCT system. From the measured organ dose, effective dose to patients were calculated according to the International Commission on Radiological Protection 103 report recommendations.

Results

For H&N, chest and pelvis scans, the organ doses were in the range of 0.03-3.43 mGy, 6.04-22.94 mGy and 2.5-25.28 mGy, respectively. The calculated effective doses were 0.25 mSv, 5.56 mSv and 4.72 mSv, respectively.

Conclusion

The obtained results were consistent with the most published studies in the literature. Although the doses to patient organs from the kV CBCT system were relatively low when compared with the prescribed treatment dose, the amount of delivered dose should be monitored and recorded carefully in order to avoid secondary cancer risk, especially in pediatric examinations.

Tables for effective dose assessment from diagnostic radiology (period 1946-1995) in epidemiologic studies

Diagnostic radiology is a leading cause of man-made radiation exposure to the population. It is an important factor in many epidemiological studies as variable of interest or as potential confounder. The effective dose as a risk related quantity is the most often stated patient dose. Nevertheless, there exists no comprehensive quantification model for retrospective analysis for this quantity. This paper gives a catalog of effective dose values for common and rare examinations and demonstrates how to modify the dose values to adapt them to different calendar years using a quantification concept already used for retrospective analysis of the red bone marrow dose. It covers the time period of 1946 to 1995 and allows considering technical development and different practical standards over time. For an individual dose assessment, if the dose area product is known, factors are given for most examinations to convert the dose area product into the effective dose. Additionally factors are stated for converting the effective dose into the red bone marrow dose or vice versa.

Comparison of CBCT conversion methods for dose calculation in the head and neck region

The purpose of this study was to compare different methods of CBCT conversion respect to dose calculation accuracy. Twelve head and neck cancer patients treated with VMAT using simultaneous integrated boost technique were selected for the study. For each patient a planning CT (pCT), a control. CT acquired in the fourth week of treatment and a CBCT scan acquired on the closest day with the control CT were used. In order to re-calculate dose directly on CBCT image sets, a population based approach (CBCTPop) and a Histogram Matching (HM) approach based on rigid (CBCTHM-R) and deformable registration (CBCTHM-D) were used. Additionally, virtual CTs (vCTs) were generated using two deformable image registration algorithms (CTELX and CTANC) of the planning CT to the CBCT by using two different deformable image registration (DIR) algorithms. The corresponding control CTs were selected as ground truth and dose distributions on CBCT were analyzed using 3D global gamma index analysis applying a threshold of 10% with respect to the prescribed dose. Using the 2%/2mm gamma criterion, the results were 89.9%(±8.3%), 94.1%(±5.0%), 94.3%(±5.7%), 96.1%(±3.9%), 93.4%(±6.3%) for the CBCTPop, CBCTHM-R, CBCTHM-D, CTELX and CTANC, respectively. On average, the HM and DIR techniques showed a higher accuracy compared to the population based approach, but Kruskal-Wallis test did not show significant difference among the investigated dose calculation techniques assuming p<0.05. More sophisticated CBCT dose calculation methods seem to improve the dose calculation accuracy, but statistical significance remains to be demonstrated.